Aion Financial Statements From 2010 to 2026
| ANTCF Stock | USD 0 0.00 0.00% |
Check Aion Therapeutic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aion Therapeutic's main balance sheet or income statement drivers, such as , as well as many indicators such as . Aion financial statements analysis is a perfect complement when working with Aion Therapeutic Valuation or Volatility modules.
Aion |
Aion Therapeutic Company Shares Owned By Insiders Analysis
Aion Therapeutic's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Aion Therapeutic Shares Owned By Insiders | 17.68 % |
Most of Aion Therapeutic's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aion Therapeutic is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 17.682% of Aion Therapeutic are shares owned by insiders. This is 16.48% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares owned by insiders for all United States stocks is 75.24% lower than that of the firm.
Aion Therapeutic Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Aion Therapeutic's current stock value. Our valuation model uses many indicators to compare Aion Therapeutic value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aion Therapeutic competition to find correlations between indicators driving Aion Therapeutic's intrinsic value. More Info.Aion Therapeutic is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aion Therapeutic's earnings, one of the primary drivers of an investment's value.About Aion Therapeutic Financial Statements
Aion Therapeutic stakeholders use historical fundamental indicators, such as Aion Therapeutic's revenue or net income, to determine how well the company is positioned to perform in the future. Although Aion Therapeutic investors may analyze each financial statement separately, they are all interrelated. For example, changes in Aion Therapeutic's assets and liabilities are reflected in the revenues and expenses on Aion Therapeutic's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Aion Therapeutic. Please read more on our technical analysis and fundamental analysis pages.
Aion Therapeutic Inc., a pharmaceutical company, offer medical cannabis products in Canada. Aion Therapeutic Inc. was incorporated in 2011 and is headquartered in Toronto, Canada. Aion Therapeutic is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Aion Pink Sheet
Aion Therapeutic financial ratios help investors to determine whether Aion Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Aion with respect to the benefits of owning Aion Therapeutic security.